Integrated network analysis of transcriptomic and proteomic data in psoriasis

BMC Systems Biology

Volumn 4, Issue , 2010, Pages

  Piruzian, Eleonora ^a   Bruskin, Sergey ^a   Ishkin, Alex ^a,b   Abdeev, Rustam ^c   Moshkovskii, Sergey ^d   Melnik, Stanislav ^d   Nikolsky, Yuri ^b   Nikolskaya, Tatiana ^a,b  

^a VAVILOV INSTITUTE OF GENERAL GENETICS   (Russian Federation)

^b GeneGo bioinformatics software Inc   (United States)

^c CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

^d INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BIOLOGICAL MODEL; BIOPSY; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; PROTEOMICS; PSORIASIS; SKIN; STATISTICAL MODEL; SYSTEMS BIOLOGY;

ADULT; BIOPSY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; MALE; MODELS, GENETIC; MODELS, STATISTICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; PSORIASIS; SKIN; SYSTEMS BIOLOGY; TRANSCRIPTION, GENETIC;

EID: 77950632103     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-4-41     Document Type: Article

References (86)

1. Boehncke WH, et al. Pulling the trigger on psoriasis. Nature 1996, 379(6568):777. 10.1038/379777a0, 8587600.
2. Ortonne JP. Aetiology and pathogenesis of psoriasis. Br J Dermatol 1996, 135(Suppl 49):1-5. 10.1111/j.1365-2133.1996.tb15660.x, 9035700.
3. Pastore S, et al. Biological drugs targeting the immune response in the therapy of psoriasis. Biologics 2008, 2(4):687-97. 2727880, 19707449.
4. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007, 6(8):515-9. 10.1016/j.autrev.2006.12.002, 17854741.
5. Oestreicher JL, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001, 1(4):272-87.
6. Bowcock AM, et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001, 10(17):1793-805. 10.1093/hmg/10.17.1793, 11532989.
7. Zhou X, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003, 13(1):69-78.
8. Quekenborn-Trinquet V, et al. Gene expression profiles in psoriasis: analysis of impact of body site location and clinical severity. Br J Dermatol 2005, 152(3):489-504. 10.1111/j.1365-2133.2005.06384.x, 15787818.
9. Nikolskaya T, et al. Network analysis of human glaucomatous optic nerve head astrocytes. BMC Med Genomics 2009, 2:24. 10.1186/1755-8794-2-24, 19426536, 2705386.
10. Nikolsky Y, Nikolskaya T, Bugrim A. Biological networks and analysis of experimental data in drug discovery. DrugDiscov Today 2005, 10(9):653-62.
11. Bhavnani SK, et al. Network analysis of genes regulated in renal diseases: implications for a molecular-based classification. BMC Bioinformatics 2009, 10(Suppl 9):S3. 10.1186/1471-2105-10-S9-S3, 2745690, 19761573.
12. Ideker T, Sharan R. Protein networks in disease. Genome Res 2008, 18(4):644-52. 10.1101/gr.071852.107, 18381899.
13. Chuang HY, et al. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007, 3:140. 10.1038/msb4100180, 2063581, 17940530.
14. Cox B, Kislinger T, Emili A. Integrating gene and protein expression data: pattern analysis and profile mining. Methods 2005, 35(3):303-14. 10.1016/j.ymeth.2004.08.021, 15722226.
15. Wise LH, Lanchbury JS, Lewis CM. Meta-analysis of genome searches. Ann Hum Genet 1999, 63(Pt 3):263-72. 10.1046/j.1469-1809.1999.6330263.x, 10738538.
16. Ghosh D, et al. Statistical issues and methods for meta-analysis of microarray data: a case study in prostate cancer. Funct Integr Genomics 2003, 3(4):180-8. 10.1007/s10142-003-0087-5, 12884057.
17. Warnat P, Eils R, Brors B. Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics 2005, 6:265. 10.1186/1471-2105-6-265, 1312314, 16271137.
18. Hack CJ. Integrated transcriptome and proteome data: the challenges ahead. Brief Funct Genomic Proteomic 2004, 3(3):212-9. 10.1093/bfgp/3.3.212, 15642185.
19. Menezes R, et al. Integrated analysis of DNA copy number and gene expression microarray data using gene sets. BMC Bioinformatics 2009, 10(1):203. 10.1186/1471-2105-10-203, 2753845, 19563656.
20. Gravel P, Golaz O. Two-Dimensional PAGE Using Carrier Ampholyte pH Gradients in the First Dimension. The Protein Protocols Handbook 1996, 127-132.
21. Mortz E, et al. Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionization-time of flight analysis. Proteomics 2001, 1(11):1359-63. 10.1002/1615-9861(200111)1:11<1359::AID-PROT1359>3.0.CO;2-Q, 11922595.
22. Yao Y, et al. Type I interferon: potential therapeutic target for psoriasis?. PLoS One 2008, 3(7):e2737. 10.1371/journal.pone.0002737, 2481274, 18648529.
23. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B, Methodological 1995, 57(1):289-300.
24. Dezso Z, et al. Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst Biol 2009, 3:36. 10.1186/1752-0509-3-36, 2678983, 19309513.
25. Pihur V, Datta S. RankAggreg, an R package for weighted rank aggregation. BMC Bioinformatics 2009, 10:62. 10.1186/1471-2105-10-62, 2669484, 19228411.
26. Leigh IM, et al. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. The British journal of dermatology 1995, 133(4):501-511. 10.1111/j.1365-2133.1995.tb02696.x, 7577575.
27. Madsen P, et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin. The Journal of investigative dermatology 1991, 97(4):701-712. 10.1111/1523-1747.ep12484041, 1940442.
28. Vorum H, et al. Expression and divalent cation binding properties of the novel chemotactic inflammatory protein psoriasin. Electrophoresis 1996, 17(11):1787-96. 10.1002/elps.1150171118, 8982613.
29. Takeda A, et al. Overexpression of serpin squamous cell carcinoma antigens in psoriatic skin. J Invest Dermatol 2002, 118(1):147-54. 10.1046/j.0022-202x.2001.01610.x, 11851888.
30. Nikolsky Y, et al. Functional analysis of OMICs data and small molecule compounds in an integrated "knowledge-based" platform. Methods in molecular biology (Clifton, N.J.) 2009, 563:177-196. full_text, 19597786.
31. Ghavami S, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. Journal of leukocyte biology 2008, 83(6):1484-1492. 10.1189/jlb.0607397, 2737328, 18339893.
32. Schreiber J, et al. Coordinated binding of NF-kappaB family members in the response of human cells to lipopolysaccharide. Proc Natl Acad Sci USA 2006, 103(15):5899-904. 10.1073/pnas.0510996103, 1426243,1426243, 16595631.
33. Tsuruta D. NF-kappaB links keratinocytes and lymphocytes in the pathogenesis of psoriasis. Recent Pat Inflamm Allergy Drug Discov 2009, 3(1):40-8. 10.2174/187221309787158399, 19149745.
34. Sano S, Chan KS, DiGiovanni J. Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. J Dermatol Sci 2008, 50(1):1-14. 10.1016/j.jdermsci.2007.05.016, 17601706.
35. Ghoreschi K, Mrowietz U, Rocken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med 2003, 81(8):471-80. 10.1007/s00109-003-0460-9, 12879154.
36. Piruzian ES, et al. [The comparative analysis of psoriasis and Crohn disease molecular-genetical processes under pathological conditions]. Mol Biol (Mosk) 2009, 43(1):175-9.
37. Gandarillas A, Watt FM. c-Myc promotes differentiation of human epidermal stem cells. Genes Dev 1997, 11(21):2869-82. 10.1101/gad.11.21.2869, 316650, 9353256.
38. Arnold I, Watt FM. c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 2001, 11(8):558-68. 10.1016/S0960-9822(01)00154-3, 11369200.
39. Lohwasser C, et al. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol 2006, 126(2):291-9. 10.1038/sj.jid.5700070, 16374460.
40. Santilli F, et al. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 2009, 16(8):940-52. 10.2174/092986709787581888, 19275604.
41. Nikolsky Y, et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer research 2008, 68(22):9532-9540. 10.1158/0008-5472.CAN-08-3082, 19010930.
42. Nikolskaya T, et al. Network analysis of human glaucomatous optic nerve head astrocytes. BMC medical genomics 2009, 2(1):24. 10.1186/1755-8794-2-24, 2705386, 19426536.
43. Le Naour F, et al. Profiling changes in gene expression during differentiation and maturation of monocyte-derived dendritic cells using both oligonucleotide microarrays and proteomics. J Biol Chem 2001, 276(21):17920-31. 10.1074/jbc.M100156200, 11279020.
44. Steiling K, et al. Comparison of proteomic and transcriptomic profiles in the bronchial airway epithelium of current and never smokers. PLoS One 2009, 4(4):e5043. 10.1371/journal.pone.0005043, 2664466, 19357784.
45. Conway JP, Kinter M. Proteomic and transcriptomic analyses of macrophages with an increased resistance to oxidized low density lipoprotein (oxLDL)-induced cytotoxicity generated by chronic exposure to oxLDL. Mol Cell Proteomics 2005, 4(10):1522-40. 10.1074/mcp.M500111-MCP200, 16006650.
46. Di Pietro C, et al. The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma. BMC Med Genomics 2009, 2(1):20. 10.1186/1755-8794-2-20, 2683874, 19402918.
47. Mijalski T, et al. Identification of coexpressed gene clusters in a comparative analysis of transcriptome and proteome in mouse tissues. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(24):8621-8626. 10.1073/pnas.0407672102, 1143582,1143582, 15939889.
48. Habermann JK, et al. Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer 2007, 46(1):10-26. 10.1002/gcc.20382, 17044061.
49. Chen YR, et al. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res 2006, 5(10):2727-42. 10.1021/pr060212g, 17022644.
50. Shachaf CM, et al. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res 2008, 68(13):5132-42. 10.1158/0008-5472.CAN-07-6192, 18593912.
51. Zhao C, et al. Identification of novel functional differences in monocyte subsets using proteomic and transcriptomic methods. Journal of Proteome Research 2009, 8(8):4028-4038. 10.1021/pr900364p, 19514703.
52. Gerling IC, et al. New data analysis and mining approaches identify unique proteome and transcriptome markers of susceptibility to autoimmune diabetes. Mol Cell Proteomics 2006, 5(2):293-305.
53. Zheng PZ, et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA 2005, 102(21):7653-8. 10.1073/pnas.0502825102, 1140456, 15894607.
54. Zhao C, et al. Identification of Novel Functional Differences in Monocyte Subsets Using Proteomic and Transcriptomic Methods. J Proteome Res 2009,
55. Reichrath J, et al. Expression of integrin subunits and CD44 isoforms in psoriatic skin and effects of topical calcitriol application. J Cutan Pathol 1997, 24(8):499-506. 10.1111/j.1600-0560.1997.tb01324.x, 9331896.
56. Kelly R, Marsden RA, Bevan D. Exacerbation of psoriasis with GM-CSF therapy. Br J Dermatol 1993, 128(4):468-9. 10.1111/j.1365-2133.1993.tb00218.x, 8494766.
57. Gu J, et al. A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. Rheumatology (Oxford) 2002, 41(7):759-66. 10.1093/rheumatology/41.7.759, 12096225.
58. Reischl J, et al. Increased expression of Wnt5a in psoriatic plaques. J Invest Dermatol 2007, 127(1):163-9. 10.1038/sj.jid.5700488, 16858420.
59. Shiina T, et al. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet 2009, 54(1):15-39. 10.1038/jhg.2008.5, 19158813.
60. Asadullah K, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998, 101(4):783-94. 10.1172/JCI1476, 508626, 9466973.
61. Cancino-Diaz JC, et al. Interleukin-13 receptor in psoriatic keratinocytes: overexpression of the mRNA and underexpression of the protein. J Invest Dermatol 2002, 119(5):1114-20. 10.1046/j.1523-1747.2002.19509.x, 12445201.
62. Pietrzak A, et al. Genes and structure of selected cytokines involved in pathogenesis of psoriasis. Folia Histochem Cytobiol 2008, 46(1):11-21. 10.2478/v10042-008-0002-y, 18296259.
63. Martin R. Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases?. Trends Pharmacol Sci 2003, 24(12):613-6. 10.1016/j.tips.2003.10.006, 14654299.
64. Penna G, et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005, 106(10):3490-7. 10.1182/blood-2005-05-2044, 16030186.
65. Fu X, et al. Estimating accuracy of RNA-Seq and microarrays with proteomics. BMC Genomics 2009, 10(1):161. 10.1186/1471-2164-10-161, 2676304, 19371429.
66. Foell D, et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003, 42(11):1383-9. 10.1093/rheumatology/keg385, 12832707.
67. Horuk R. BX471: a CCR1 antagonist with anti-inflammatory activity in man. Mini Rev Med Chem 2005, 5(9):791-804. 10.2174/1389557054867057, 16178722.
68. Vestergaard C, et al. Expression of CCR2 on monocytes and macrophages in chronically inflamed skin in atopic dermatitis and psoriasis. Acta Derm Venereol 2004, 84(5):353-8. 10.1080/00015550410034444, 15370700.
69. Rottman JB, et al. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001, 81(3):335-47.
70. de Groot M, et al. Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res 2007, 299(7):305-13. 10.1007/s00403-007-0764-7, 1950346, 17647003.
71. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001, 345(4):248-55. 10.1056/NEJM200107263450403, 11474662.
72. De Rie MA, et al. Expression of the T-cell activation antigens CD27 and CD28 in normal and psoriatic skin. Clin Exp Dermatol 1996, 21(2):104-11. 10.1111/j.1365-2230.1996.tb00030.x, 8759195.
73. Prens E, et al. Adhesion molecules and IL-1 costimulate T lymphocytes in the autologous MECLR in psoriasis. Arch Dermatol Res 1996, 288(2):68-73. 10.1007/BF02505046, 8932583.
74. Haider AS, et al. Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol 2007, 178(11):7442-9.
75. Castelijns FA, et al. The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis. J Am Acad Dermatol 1999, 40(6 Pt 1):901-9. 10.1016/S0190-9622(99)70077-0, 10365920.
76. Johansen C, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 2009, 160(2):319-24. 10.1111/j.1365-2133.2008.08902.x, 19016708.
77. Debets R, et al. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 1997, 158(6):2955-63.
78. Schulz BS, et al. Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol 1993, 151(8):4399-406.
79. Guttman-Yassky E, et al. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol 2008, 128(5):1182-91. 10.1038/jid.2008.4, 18239614.
80. Sjogren F, et al. Expression and function of beta 2 integrin CD11B/CD18 on leukocytes from patients with psoriasis. Acta Derm Venereol 1999, 79(2):105-10. 10.1080/000155599750011291, 10228626.
81. Curry JL, et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003, 127(2):178-86.
82. Vissers WH, et al. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 2004, 150(5):852-9. 10.1111/j.1365-2133.2004.05863.x, 15149496.
83. Patterson AM, et al. Differential expression of syndecans and glypicans in chronically inflamed synovium. Ann Rheum Dis 2008, 67(5):592-601. 10.1136/ard.2006.063875, 2563418, 17545191.
84. Wakita H, Takigawa M. E-selectin and vascular cell adhesion molecule-1 are critical for initial trafficking of helper-inducer/memory T cells in psoriatic plaques. Arch Dermatol 1994, 130(4):457-63. 10.1001/archderm.130.4.457, 7513146.
85. Chu A, et al. Tissue specificity of E- and P-selectin ligands in Th1-mediated chronic inflammation. J Immunol 1999, 163(9):5086-93.
86. Seung NR, et al. Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4, and T-cell receptor gammadelta in plaque and guttate psoriasis. J Cutan Pathol 2007, 34(12):903-11. 10.1111/j.1600-0560.2007.00756.x, 18001412.